KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Depreciation (2021 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Accumulated Depreciation for 4 consecutive years, with $13.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation rose 19.67% to $13.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $13.5 million, a 19.67% increase, with the full-year FY2024 number at $13.5 million, up 19.67% from a year prior.
  • Accumulated Depreciation was $13.5 million for Q4 2024 at Xenon Pharmaceuticals, up from $11.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $13.5 million in Q4 2024 to a low of $8.7 million in Q4 2022.
  • A 4-year average of $11.7 million and a median of $12.3 million in 2021 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: tumbled 34.79% in 2022, then rose 29.25% in 2023.
  • Xenon Pharmaceuticals' Accumulated Depreciation stood at $13.4 million in 2021, then crashed by 34.79% to $8.7 million in 2022, then grew by 29.25% to $11.3 million in 2023, then grew by 19.67% to $13.5 million in 2024.
  • Per Business Quant, the three most recent readings for XENE's Accumulated Depreciation are $13.5 million (Q4 2024), $11.3 million (Q4 2023), and $8.7 million (Q4 2022).